 In 1997, the FDA issued new guidelines that intended to make DTCM on radio and television less burdensome.In particular, the FDA clarified that informing the audience of where the "brief summary" can be obtained (such as a magazine ad, phone hotline, or website) constituted "adequate provision" of risk information, and thus relieved them from being included in the ad.The FDA also recognized reminder ads (such as the aforementioned Claritin ad) as not being subject to these rules, since they do not make any claims or statements regarding the indications and benefits of the medication.